50 drugs reach their earliest generic-entry date in 2042

Jan 2042 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Xelstrym · 4 strengths dextroamphetamine	dextroamphetamine	Noven Pharms Inc	215401	6 Jan 2042	patent
Lasix Onyu furosemide	furosemide	Sq Innovation	217294	10 Jan 2042	patent
Galafold migalastat hydrochloride	migalastat hydrochloride	Amicus Therap Us	208623	11 Jan 2042	patent, carve-out possible
Rasonque · 2 strengths daraxonrasib	daraxonrasib	Revolution Medicines	220910	24 Jan 2042	patent

Feb 2042 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Tyvaso treprostinil	treprostinil	United Therap	022387	3 Feb 2042	patent, carve-out possible
Tyvaso Dpi · 5 strengths treprostinil	treprostinil	United Therap	214324	3 Feb 2042	patent, carve-out possible

Mar 2042 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Sephience · 2 strengths sepiapterin	sepiapterin	Ptc Therap	219666	6 Mar 2042	patent, carve-out possible
Ayvakit · 3 strengths avapritinib	avapritinib	Blueprint Medicines	212608	8 Mar 2042	patent, carve-out possible
Lumryz · 4 strengths sodium oxybate	sodium oxybate	Alkermes Inc	214755	16 Mar 2042	patent, carve-out possible
Uzedy · 7 strengths risperidone	risperidone	Teva	213586	17 Mar 2042	patent, carve-out possible

Apr 2042 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Vevye cyclosporine	cyclosporine	Harrow Eye	217469	1 Apr 2042	patent
Sezaby phenobarbital sodium	phenobarbital sodium	Sun Pharm Inds Inc	215910	7 Apr 2042	patent
Defencath · 2 strengths heparin sodium; taurolidine	heparin sodium; taurolidine	Cormedix	214520	15 Apr 2042	patent
Axumin fluciclovine f-18	fluciclovine f-18	Blue Earth	208054	23 Apr 2042	patent, carve-out possible

May 2042 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Xocova ensitrelvir	ensitrelvir	Shionogi	220442	1 May 2042	patent
Ontralfy tizanidine hydrochloride	tizanidine hydrochloride	Fidelity Biopharma	216190	7 May 2042	patent
Flyrcado flurpiridaz f-18	flurpiridaz f-18	Ge Hlthcare	215168	13 May 2042	patent
Clotic clotrimazole	clotrimazole	Carwin Pharm Assoc	217628	26 May 2042	patent
Otezla Xr apremilast	apremilast	Amgen Inc	210745	27 May 2042	patent
Talicia amoxicillin; omeprazole magnesium; rifabutin	amoxicillin; omeprazole magnesium; rifabutin	Talicia Holdings	213004	27 May 2042	patent, carve-out possible

Jun 2042 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Valtoco · 3 strengths diazepam	diazepam	Neurelis Inc	211635	10 Jun 2042	patent, carve-out possible
Nubeqa darolutamide	darolutamide	Bayer Healthcare	212099	17 Jun 2042	patent
Welireg belzutifan	belzutifan	Merck Sharp Dohme	215383	30 Jun 2042	patent

Jul 2042 · 7

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Gemtesa vibegron	vibegron	Sumitomo Pharma Am	213006	6 Jul 2042	patent, carve-out possible
Voxzogo · 3 strengths vosoritide	vosoritide	Biomarin Pharm	214938	11 Jul 2042	patent, carve-out possible
Rezurock belumosudil mesylate	belumosudil mesylate	Kadmon Pharms Llc	214783	14 Jul 2042	patent, carve-out possible
Cardamyst etripamil	etripamil	Milestone Pharms Usa	218571	15 Jul 2042	patent, carve-out possible
Javadin clonidine hydrochloride	clonidine hydrochloride	Azurity	220256	15 Jul 2042	patent
Myqorzo · 4 strengths aficamten	aficamten	Cytokinetics	219083	15 Jul 2042	patent, carve-out possible
Vivimusta bendamustine hydrochloride	bendamustine hydrochloride	Azurity	212209	29 Jul 2042	patent

Aug 2042 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Opvee nalmefene hydrochloride	nalmefene hydrochloride	Indivior	217470	4 Aug 2042	patent, carve-out possible
Zoryve roflumilast	roflumilast	Arcutis	217242	19 Aug 2042	patent

Sep 2042 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Epidiolex cannabidiol	cannabidiol	Jazz Pharms Res	210365	24 Sep 2042	patent, carve-out possible
Qulipta atogepant	atogepant	Abbvie	215206	27 Sep 2042	patent, carve-out possible
Jideytro · 2 strengths zidesamtinib	zidesamtinib	Nuvalent	220185	30 Sep 2042	patent
Ztalmy ganaxolone	ganaxolone	Immedica Pharma	215904	30 Sep 2042	patent, carve-out possible

Oct 2042 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Qinlock ripretinib	ripretinib	Deciphera Pharms	213973	6 Oct 2042	patent, carve-out possible

Nov 2042 · 7

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Myfembree estradiol; norethindrone acetate; relugolix	estradiol; norethindrone acetate; relugolix	Sumitomo Pharma Am	214846	5 Nov 2042	patent
Yuvezzi brimonidine tartrate; carbachol	brimonidine tartrate; carbachol	Visus	220142	10 Nov 2042	patent
Yorvipath · 3 strengths palopegteriparatide	palopegteriparatide	Ascendis Pharma Bone	216490	12 Nov 2042	patent
Yuviwel · 3 strengths navepegritide	navepegritide	Ascendis	219164	12 Nov 2042	patent
Ibsrela tenapanor hydrochloride	tenapanor hydrochloride	Ardelyx Inc	211801	26 Nov 2042	patent
Tagrisso · 2 strengths osimertinib mesylate	osimertinib mesylate	Astrazeneca	208065	26 Nov 2042	patent, carve-out possible
Xphozah · 2 strengths tenapanor hydrochloride	tenapanor hydrochloride	Ardelyx Inc	213931	26 Nov 2042	patent

Dec 2042 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Inqovi cedazuridine; decitabine	cedazuridine; decitabine	Taiho Oncology	212576	10 Dec 2042	patent, carve-out possible
Blujepa gepotidacin mesylate	gepotidacin mesylate	Glaxosmithkline	218230	13 Dec 2042	patent
Tryptyr acoltremon	acoltremon	Alcon Labs Inc	217370	16 Dec 2042	patent
Revuforj · 3 strengths revumenib citrate	revumenib citrate	Syndax	218944	18 Dec 2042	patent
Avmapki Fakzynja Co-Pack (Copackaged) avutometinib potassium; defactinib hydrochloride	avutometinib potassium; defactinib hydrochloride	Verastem Inc	219616	29 Dec 2042	patent
Sunosi · 2 strengths solriamfetol hydrochloride	solriamfetol hydrochloride	Axsome Malta	211230	30 Dec 2042	patent, carve-out possible